{"id":41,"date":"2014-03-31T04:32:31","date_gmt":"2014-03-31T04:32:31","guid":{"rendered":"https:\/\/scientificspam.net\/?p=41"},"modified":"2014-03-31T04:32:31","modified_gmt":"2014-03-31T04:32:31","slug":"listed-gtcbio-gtc-conferences","status":"publish","type":"post","link":"https:\/\/www.scientificspam.net\/?p=41","title":{"rendered":"LISTED: GTCbio \/ GTC Conferences"},"content":{"rendered":"

This is a spammer that’s been notice in a presentation on managing email<\/a> (slide 18) by the University of Texas Medical Branch. We would, of course, recommend that nobody nowhere attempt to unsubscribe from spam, which is a position widely accepted<\/a> in the DNSBL circles.<\/p>\n


\nListed IP: 216.40.218.178<\/p>\n

Spam headers:<\/p>\n

From ddmc@lifescienceshome.com Tue Mar  4 21:mm:ss 2014\r\nReturn-Path: <ddmc@lifescienceshome.com>\r\nReceived: from server1 (server1.bioprovider.com [216.40.218.178])\r\n        by x (Postfix) with SMTP id x\r\n        for <x>; Tue,  4 Mar 2014 21:mm:ss +0000 (GMT)\r\nReceived: from server1[127.0.0.1] by server1[127.0.0.1]\r\n        (SMTPD32); Tue, 4 Mar 2014 15:mm:ss -0600\r\nReply-To: ddmc@lifescienceshome.com\r\nMessage-ID: <x@lifescienceshome.com>\r\nFrom: Drug Design and Medicinal Chemistry <ddmc@lifescienceshome.com>\r\nTo: x\r\nSubject: Drug Design & Medicinal Chemistry Conference - Top 5 Presentations\r\nDate: Tue, 4 Mar 2014 15:mm:ss -0600\r\nMIME-Version: 1.0\r\nContent-Type: multipart\/alternative;\r\n        boundary=\"----=SPLITOR00A_001_x\"\r\nX-Status: F\r\nContent-Length: x\r\nLines: 847<\/pre>\n
Spam contents:<\/p>\n
If you can’t view this page, please visit: http:\/\/www.gtcbio.com\/newsletter\/DDMC14II-w.htm x-#<\/p>\n
20% early bird discount ends March 8, 2014!
\nDrug Design & Medicinal Chemistry Conference
\nMay 8-9, 2014 | Berlin, Germany
\nhttp:\/\/www.gtcbio.com\/drugdesign<\/p>\n
Dear Colleague,<\/p>\n
We wanted to let you know the 20% early bird discount will be ending soon. Join colleagues from industry and academia at the Drug Design & Medicinal Chemistry Conference, May 8-9, 2014 at the Kempinski Bristol Hotel in Berlin, Germany, to learn about rising targets in protein-protein interactions, epigenetics, and in the ubiquitin proteasome system.\u00a0 Hear about the latest technologies in drug discovery and using novel computational methods in medicinal chemistry.<\/p>\n
Here are 5 presentations we don’t want you to miss:
\nKeynote Presentation: The Challenge to Block the Protein-Protein Interface of a Homodimer by Small Molecules
\nGerhard Klebe, Professor of Pharmaceutical Chemistry, University of Marburg
\nDr. Klebe’s lab showed that the tRNA-modifying enzyme Tgt, a putative target to fight Shigellosis, is only functional as a homodimer.<\/p>\n
Local Environment of Fluorine (LEF): Screening and Drug Design
\nAnna Vulpetti, Senior Investigator, Novartis
\nThis talk will discuss a novel fluorine fingerprint descriptor encoding the local environment of fluorine (LEF) for interpreting protein-fluorine interactions and for selecting the proper fluorine type for the desired interaction.<\/p>\n
Implementation of Flow Technologies in Drug Discovery at Janssen
\nJes\u00fas Alc\u00e1zar, Senior Scientist, Janssen
\nAn H-CUBE hydrogenation reactor was successfully implemented as a first approach to flow technologies. Dr. Alc\u00e1zar will discuss its impact on drug discovery and the collaborations with external partners to achieve this success.<\/p>\n
Data-Driven Medicinal Chemistry in the Era of Big-Data
\nScott Lusher, Director of Applied eScience, Netherlands eScience Center
\nDr. Lusher will share how data-driven medicinal chemistry approaches have the potential to improve decision-making in drug discovery projects.<\/p>\n
Using Bioactivity Databases and Computer Algorithms for Target Deconvolution and Compound Design
\nAndreas Bender, Lecturer of Molecular Informatics and Drug Design, University of Cambridge
\nCheminformatics algorithms trained on large chemogenomics databases can be employed to support target deconvolution in high-content screening as well as organism-based screens using Xenopus laevis as well as phenotypic data obtained from rat models.<\/p>\n
Register before March 8, 2014 and save 20% off the registration price or use the discount code rcdvb to register three colleagues for the price of two.<\/p>\n
The Drug Design & Medicinal Chemistry is part of the Europe Drug Discovery Summit which includes two other conferences:
\nTissue Models & Drug Screening\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (May 6-7, 2014)
\nProtein Kinases in Drug Discovery\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 l(May 8-9, 2014)<\/p>\n
Sign up for a summit pass for access to all three tracks!<\/p>\n
DISTINGUISHED SPEAKERS<\/p>\n
Gerhard Klebe, Professor, Institute of Pharmaceutical Chemistry, University of Marburg – KEYNOTE<\/p>\n
Jes\u00fas Alc\u00e1zar, Senior Scientist, Janssen<\/p>\n
Andreas Bender, Lecturer for Molecular Informatics and Drug Design, University of Cambridge<\/p>\n
Jascha Blobel, Product Manager, Intelligent Pharma<\/p>\n
Frank Boeckler, Professor, Medicinal Chemistry & Drug Design, Eberhard Karls Universit\u00e4t T\u00fcbingen<\/p>\n
Helena Danielson, Professor of Biochemistry, Uppsala University<\/p>\n
Alexander D\u00f6mling, Professor, Department of Drug Design, University of Groningen<\/p>\n
Gerhard Ecker, Professor, Department of Medicinal Chemistry, University of Vienna<\/p>\n
Darren Fayne, Senior Research Fellow, Trinity College Dublin<\/p>\n
Thomas Franch, Chief Scientific Officer, Nuevolution A\/S<\/p>\n
Antimo Gioiello, Assistant Professor, Department of Pharmaceutical Sciences, University of Perugia<\/p>\n
Nils Jakob Vest Hansen, CEO, Vipergen ApS<\/p>\n
Katherine Jones, Associate Scientist, GlaxoSmithKline<\/p>\n
Stefan Knapp, Professor, University of Oxford<\/p>\n
Daniel Kuhn, Computational Chemist, Merck KG<\/p>\n
Stig Linder, Professor of Experimental Oncology, Vice Chairman of the Department of Oncology and Pathology, Karolinska Institute<\/p>\n
Scott Lusher, Director, Applied eScience, Netherlands eScience Center<\/p>\n
\u00c9ric Marsault, Professor, Department of Pharmacology, Universit\u00e9 de Sherbrooke<\/p>\n
Ben Munoz, Vice President, Head of Medicinal Chemistry, Proteostasis Therapeutics<\/p>\n
Christian Ottmann, Associate Professor, Biomedical Engineering, Technische Universiteit Eindhoven<\/p>\n
Paula Petrone, Scientist, Roche<\/p>\n
Paul Polakis, Director, Staff Scientist, Discovery Oncology, Genentech<\/p>\n
Matthieu Schapira, Associate Professor, University of Toronto<\/p>\n
Gisbert Schneider, Professor, Institute of Pharmaceutical Sciences, ETH Z\u00fcrich<\/p>\n
Olivier Sperandio, Drug Designer, Protein-Protein Interactions, INSERM France<\/p>\n
Anna Vulpetti, Senior Investigator, Novartis<\/p>\n
Steffen Weinbrenner, Head Drug Discovery, Polyphor Ltd.<\/p>\n
Ingrid Wertz, Scientist and Project Team Leader, Department of Early Discovery Biochemistry, Genentech<\/p>\n
View the speakers webpage for the most updated list of speakers.<\/p>\n
CALL FOR PAPERS
\nTo be considered for an oral presentation, please submit an abstract by April 8, 2013. Selected presentations will be based on quality of abstract and availability.
\nSPONSORSHIP & EXHIBITOR OPPORTUNITIES<\/p>\n
GTC offers comprehensive sponsorship packages for all our meetings, including presentation opportunities, exhibit and booth space, as well as the event delegate list. All our packages can be customized to meet your company’s budget. For more information, please contact
\nAmber Kempf at 626-256-6405 x110 or spex@gtcbio.com<\/p>\n
UPCOMING CONFERENCES<\/p>\n
4th International Conference on Tumor Progression and Therapeutic Resistance | March 9-11, 2014 | Boston, MA<\/p>\n
Biomarker Summit 2014 | March 19-21, 2014 | San Diego, CA
\n7th Oncology Biomarkers
\n3rd Neurological Biomarkers
\n3rd Inflammatory & Immunological Biomarkers<\/p>\n
6th Ocular Diseases & Drug Discovery | March 20-21, 2014 | San Diego, CA<\/p>\n
Diabetes Summit 2014 | April 23-25, 2014 | Cambridge, MA
\n10% discount by March 23, 2014
\n7th Diabetes Drug Discovery & Development
\n4th Diabetes Partnering and Deal-Making<\/p>\n
Stem Cell Summit 2014 | April 23-25, 2014 | Cambridge, MA
\n10% discount by March 23, 2014
\nStem Cell Research & Regenerative Medicine
\nStem Cell Commercialization & Partnering<\/p>\n
Europe Drug Discovery Summit | May 6-9, 2014 | Berlin, Germany
\n20% discount by March 6, 2014
\nTissue Models & Drug Screening\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (May 6-7, 2014)
\n20% discount by March 8, 2014
\nDrug Design & Medicinal Chemistry\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (May 8-9, 2014)
\nProtein Kinases in Drug Discovery\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (May 8-9, 2014)<\/p>\n
Drug Discovery Summit | May 22-23, 2014 | Cambridge, MA
\n20% discount by March 22, 2014
\nGPCR Structure, Function and Drug Discovery
\nMetabolomics: Advances & Applications in Human Diseases
\nSingle Cell Analysis
\nBioanalytical Sensors<\/p>\n
Nucleic Acid Summit 2014 | June 19-20, 2014 | San Diego, CA
\n20% discount by April 19, 2014
\n4th Next Generation Sequencing
\nBioinformatics & Pharmacogenomics: Managing and Analyzing Big Data
\nNon-Coding RNAs and RNAi Research & Therapeutics
\nNucleic Acid Research and Discovery<\/p>\n
Novel Cancer Therapeutics Summit 2014 | July 7-8, 2014 | Boston, MA
\n20% discount by May 7, 2014
\n5th Cancer Targets & Therapeutics
\n3rd Oncology Partnering & Deal-Making<\/p>\n
Infectious Diseases World Summit 2014 | July 9-11, 2014 | Boston, MA
\n20% discount by May 9, 2014
\n12th Vaccines Research & Development: All Things Considered
\n11th Anti-Infectives Partnering & Deal-Making
\n3rd Influenza Research & Development<\/p>\n
This advertisement is sent to x from GTC, 635 W. Foothill Blvd, Monrovia, CA 91016. If you prefer not to receive further messages from this sender, please forward this email to remove@gtcbio.com or use the following link to unsubscribe http:\/\/gtcbio.com\/unsubscribe.php?emailid=x\n<\/p><\/blockquote>\n","protected":false},"excerpt":{"rendered":"
This is a spammer that’s been notice in a presentation on managing email (slide 18) by the University of Texas Medical Branch. We would, of course, recommend that nobody nowhere attempt to unsubscribe from spam, which is a position widely accepted in the DNSBL circles.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[21,19,20],"class_list":["post-41","post","type-post","status-publish","format-standard","hentry","category-bogus-academic-conferences","tag-bioprovider-com","tag-gtcbio-com","tag-lifescienceshome-com"],"_links":{"self":[{"href":"https:\/\/www.scientificspam.net\/index.php?rest_route=\/wp\/v2\/posts\/41","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.scientificspam.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.scientificspam.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.scientificspam.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.scientificspam.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41"}],"version-history":[{"count":3,"href":"https:\/\/www.scientificspam.net\/index.php?rest_route=\/wp\/v2\/posts\/41\/revisions"}],"predecessor-version":[{"id":44,"href":"https:\/\/www.scientificspam.net\/index.php?rest_route=\/wp\/v2\/posts\/41\/revisions\/44"}],"wp:attachment":[{"href":"https:\/\/www.scientificspam.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.scientificspam.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.scientificspam.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}